These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 25967088)

  • 1. Participation rates for organized colorectal cancer screening programmes: an international comparison.
    Klabunde C; Blom J; Bulliard JL; Garcia M; Hagoel L; Mai V; Patnick J; Rozjabek H; Senore C; Törnberg S
    J Med Screen; 2015 Sep; 22(3):119-26. PubMed ID: 25967088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
    Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
    Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing participation in colorectal cancer screening programs in Spain.
    Vanaclocha-Espi M; Ibáñez J; Molina-Barceló A; Pérez E; Nolasco A; Font R; Pérez-Riquelme F; de la Vega M; Arana-Arri E; Oceja M; Espinàs JA; Portillo I; Salas D;
    Prev Med; 2017 Dec; 105():190-196. PubMed ID: 28887191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community.
    Hughes K; Leggett B; Del Mar C; Croese J; Fairley S; Masson J; Aitken J; Clavarino A; Janda M; Stanton WR; Tong S; Newman B
    Aust N Z J Public Health; 2005 Aug; 29(4):358-64. PubMed ID: 16222934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial participation as a predictor for continuous participation in population-based colorectal cancer screening.
    Saraste D; Öhman DJ; Sventelius M; Elfström KM; Blom J; Törnberg S
    J Med Screen; 2018 Sep; 25(3):126-133. PubMed ID: 28786766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program.
    Koïvogui A; Mab GL; Benamouzig R
    Am J Gastroenterol; 2018 Dec; 113(12):1891-1899. PubMed ID: 30337703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test.
    Symonds EL; Cock C; Meng R; Cole SR; Fraser RJL; Young GP
    Eur J Cancer Prev; 2018 Sep; 27(5):425-432. PubMed ID: 28368949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.
    Toes-Zoutendijk E; Portillo I; Hoeck S; de Brabander I; Perrin P; Dubois C; van Leerdam M; Lansdorp-Vogelaar I; Bardou M
    J Med Screen; 2020 Jun; 27(2):68-76. PubMed ID: 31645173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.